Abstract

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a substantial number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered Report describes the proposed replication plan of experiments from "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations" by Sharma and colleagues, published in Cell in 2010 (Sharma et al., 2010). Sharma and colleagues demonstrated that prolonged exposure of cancer cells to TKIs give rise to small populations of "drug tolerant persisters" (DTPs) (Figure 1B-C) that were reversed during subsequent maintenance under drug-free conditions (Figures 1E, 2B and 2E). DTPs exhibited reduced histone acetylation and sensitivity to HDAC inhibitors (HDIs) (Figure 4A-B). Drug sensitivity was restored with co-treatment of either HDIs or an IGF-1R inhibitor, in combination with TKIs (Figure 5A-B). Inhibition of IGF-1R activation also led to decreased KDM5A expression and restoration of H3K4 methylation, suggesting a direct link between the IGF-1R signaling pathway and KDM5A function (Figure 7A, 7C, and 7I). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife.

Highlights

  • The effectiveness of chemotherapy for the treatment of cancer is limited by the acquisition of drug resistance

  • These data indicate that acquired Tyrosine kinase inhibitors (TKIs) resistance might not require permanent genetic alterations, an observation further supported by the fact that PC9 drug tolerance was not the result of genetic alterations resulting in enhanced drug efflux (Figure 1E)

  • Work by Murakami and colleagues demonstrated a similar upregulation in IGF-1R activity in persistent TKI-selected non-small cell lung cancer (NSCLC) cells, this phenotype was not attributed to chromatin modifications (Murakami et al, 2014)

Read more

Summary

Introduction

The effectiveness of chemotherapy for the treatment of cancer is limited by the acquisition of drug resistance. TKI sensitivity was fully restored when PC9 DTPs were propagated in drug-free conditions (Figure 2E) These data indicate that acquired TKI resistance might not require permanent genetic alterations, an observation further supported by the fact that PC9 drug tolerance was not the result of genetic alterations resulting in enhanced drug efflux (Figure 1E). Work by Murakami and colleagues demonstrated a similar upregulation in IGF-1R activity in persistent TKI-selected NSCLC cells, this phenotype was not attributed to chromatin modifications (Murakami et al, 2014). These results will be replicated in Protocols 4–9

Materials and methods
Procedure Note
Determining the doubling time of PC9 cells
Findings
Funding Funder
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call